(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived. - 2Focus on Yourself: Wellbeing and Taking care of oneself Practices
- 35 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- 45 Great and High Evaluated Scene Configuration Administrations For 2024
- 5A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- Vote in favor of your Number one kind of juice
- Evaluated Smartwatches for Wellness Devotees
- What did the gov’t approve for Israel’s 2026 state budget?
- 21 Incredibly Interesting Contemplations To Observe Consistently
- How comfort foods trigger pleasure in our brains
- Turning to turkey’s tryptophan to boost mood? Not so fast
- How HIV/AIDS got its name − the words Americans used for the crisis were steeped in science, stigma and religious language
- 10 Demonstrated Tips to Boost Your New Android Cell phone: A Thorough Aide
- An Aide On Upgrading Your FICO rating
